{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:42:22Z","timestamp":1775151742943,"version":"3.50.1"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0061102","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T20:49:00Z","timestamp":1366231740000},"page":"e61102","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors &amp; In Silico Phenotypic Analysis"],"prefix":"10.1371","volume":"8","author":[{"given":"Barbara A.","family":"Rath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaveh Pouran","family":"Yousef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David K.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"von Kleist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas C.","family":"Merigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-200868010-00004","article-title":"Antiretroviral therapy : optimal sequencing of therapy to avoid resistance","volume":"68","author":"JL Martinez-Cajas","year":"2008","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1468-1293.2009.00816.x","article-title":"History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change","volume":"11","author":"J Reekie","year":"2010","journal-title":"HIV Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(06)69638-4","article-title":"Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses","volume":"368","author":"R Chou","year":"2006","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nsb0495-303","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors","volume":"2","author":"R Esnouf","year":"1995","journal-title":"Nat Struct Biol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1126\/science.7532321","article-title":"Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors","volume":"267","author":"RA Spence","year":"1995","journal-title":"Science (New York, N Y )"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1128\/AAC.00741-11","article-title":"Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes","volume":"55","author":"M Frank","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e1002359","DOI":"10.1371\/journal.pcbi.1002359","article-title":"HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection","volume":"8","author":"M von Kleist","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/00002030-200109070-00013","article-title":"The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial","volume":"15","author":"EJ Fisher","year":"2001","journal-title":"AIDS"},{"key":"ref9","unstructured":"DHHS (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents <comment>Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/wwwaidsinfonihgov\/ContentFiles\/AdultandAdolescentGLpdf\" xlink:type=\"simple\">http:\/\/wwwaidsinfonihgov\/ContentFiles\/AdultandAdolescentGLpdf<\/ext-link>.1\u2013239. PP. Accessed 2012 Apr 26<\/comment>."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000331995","article-title":"Targets for inhibition of HIV replication: entry, enzyme action, release and maturation","volume":"55","author":"S Sierra-Aragon","year":"2012","journal-title":"Intervirology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1074\/jbc.M109.096529","article-title":"The acyclic 2,4-diaminopyrimidine nucleoside phosphonate acts as a purine mimetic in HIV-1 reverse transcriptase DNA polymerization","volume":"285","author":"BD Herman","year":"2010","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/AAC.00683-06","article-title":"Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors","volume":"51","author":"N Sluis-Cremer","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"ref13","first-page":"1165","article-title":"Perspective: Sign epistasis and genetic constraint on evolutionary trajectories","volume":"59","author":"DM Weinreich","year":"2005","journal-title":"Evolution"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature11510","article-title":"Epistasis as the primary factor in molecular evolution","volume":"490","author":"MS Breen","year":"2012","journal-title":"Nature"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e18204","DOI":"10.1371\/journal.pone.0018204","article-title":"HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs","volume":"6","author":"M von Kleist","year":"2011","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jmv.21085","article-title":"HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy","volume":"80","author":"N Gianotti","year":"2008","journal-title":"J Med Virol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/13543784.13.8.933","article-title":"Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy","volume":"13","author":"RW Buckheit Jr","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/01.aids.0000218542.08845.b2","article-title":"Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study)","volume":"20","author":"A Castagna","year":"2006","journal-title":"AIDS"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/v4081212","article-title":"Persistence versus Reversion of 3 TC Resistance in HIV-1 Determine the Rate of Emergence of NVP Resistance","volume":"4","author":"B Rath","year":"2012","journal-title":"Viruses"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.05487-11","article-title":"Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility","volume":"56","author":"GL Melikian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/00002030-199904160-00006","article-title":"Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development","volume":"13","author":"S Palmer","year":"1999","journal-title":"AIDS"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11633630-000000000-00000","article-title":"HIV-1 antiretroviral resistance: scientific principles and clinical applications","volume":"72","author":"MW Tang","year":"2012","journal-title":"Drugs"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1126\/science.1701568","article-title":"Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor","volume":"250","author":"VJ Merluzzi","year":"1990","journal-title":"Science"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/JVI.72.6.5303-5306.1998","article-title":"Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment","volume":"72","author":"MA Winters","year":"1998","journal-title":"J Virol"},{"key":"ref25","unstructured":"Nijhuis M, Boucher CA, Schuurman R (1995) Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 19: 178\u2013180, 182."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.7326\/0003-4819-124-12-199606150-00003","article-title":"The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients","volume":"124","author":"JM Schapiro","year":"1996","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1172\/JCI4948","article-title":"A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors","volume":"102","author":"MA Winters","year":"1998","journal-title":"J Clin Invest"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"SY Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"ref29","unstructured":"Allen LJS (2011) An introduction to stochastic processes with applications to biology. Boca Raton, FL: Chapman &amp; Hall\/CRC. xxiv, 466 p. p."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1137\/S0036144598335107","article-title":"Mathematical analysis of HIV-1 dynamics in vivo","volume":"41","author":"AS Perelson","year":"1999","journal-title":"Siam Review"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e1000720","DOI":"10.1371\/journal.pcbi.1000720","article-title":"Drug-class specific impact of antivirals on the reproductive capacity of HIV","volume":"6","author":"M von Kleist","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"ref32","unstructured":"Bonate PL (2006) Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York, NY: Springer."},{"key":"ref33","unstructured":"Norris JR (1998) Markov chains. Cambridge, UK; New York: Cambridge University Press. xvi, 237 p. p."},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Gardiner CW (2004) Handbook of stochastic methods for physics, chemistry, and the natural sciences. Berlin; New York: Springer-Verlag. xvii, 415 p. p.","DOI":"10.1007\/978-3-662-05389-8"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amc.2005.12.032","article-title":"Computing the moments of high dimensional solutions of the master equation","volume":"180","author":"S Engblom","year":"2006","journal-title":"Applied Mathematics and Computation"},{"key":"ref36","unstructured":"Gillespie DT (1992) Markov processes: an introduction for physical scientists. San Diego: Academic Press."},{"key":"ref37","unstructured":"Hogg RV, McKean JW, Craig AT (2013) Introduction to mathematical statistics. Boston: Pearson. x, 694 p."},{"key":"ref38","unstructured":"Goon A (1962) Fundamentals of statistics. Calcutta,: World Press. 401 p."},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Bonate PL (2011) Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer.","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"ref40","first-page":"156","article-title":"2011 update of the drug resistance mutations in HIV-1","volume":"19","author":"VA Johnson","year":"2011","journal-title":"Top Antivir Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"DE Bennett","year":"2009","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00002030-200106150-00007","article-title":"Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy","volume":"15","author":"N Shulman","year":"2001","journal-title":"AIDS (London, England)"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/00002030-200409030-00006","article-title":"Genetic correlates of efavirenz hypersusceptibility","volume":"18","author":"NS Shulman","year":"2004","journal-title":"AIDS (London, England)"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1097\/00002030-200304110-00007","article-title":"Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs","volume":"17","author":"DA Katzenstein","year":"2003","journal-title":"AIDS (London, England)"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/00002030-200311070-00016","article-title":"Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz","volume":"17","author":"RJ Bosch","year":"2003","journal-title":"AIDS (London, England)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00002030-200204120-00009","article-title":"Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions","volume":"16","author":"J Martinez-Picado","year":"2002","journal-title":"AIDS"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.1101786","article-title":"Evidence for positive epistasis in HIV-1","volume":"306","author":"S Bonhoeffer","year":"2004","journal-title":"Science (New York, N Y )"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e18375","DOI":"10.1371\/journal.pone.0018375","article-title":"Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1","volume":"6","author":"JP Martinez","year":"2011","journal-title":"PLoS One"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virusres.2007.12.018","article-title":"Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase","volume":"134","author":"J Ren","year":"2008","journal-title":"Virus Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1128\/AAC.01480-09","article-title":"Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine","volume":"54","author":"H Gatanaga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/JVI.75.11.4999-5008.2001","article-title":"Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy","volume":"75","author":"L Bacheler","year":"2001","journal-title":"J Virol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","author":"CJ Petropoulos","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions","volume":"81","author":"ME Cong","year":"2007","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2174\/1568026043388484","article-title":"Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase","volume":"4","author":"PL Sharma","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1086\/430709","article-title":"Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection","volume":"41","author":"TB Campbell","year":"2005","journal-title":"Clin Infect Dis"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1128\/JVI.71.6.4479-4484.1997","article-title":"Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215","volume":"71","author":"J Goudsmit","year":"1997","journal-title":"J Virol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1128\/JVI.72.5.3520-3523.1998","article-title":"Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants","volume":"72","author":"S Yerly","year":"1998","journal-title":"J Virol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1128\/JVI.75.2.595-602.2001","article-title":"Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus","volume":"75","author":"A de Ronde","year":"2001","journal-title":"J Virol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.95.20.11514","article-title":"Drug concentration heterogeneity facilitates the evolution of drug resistance","volume":"95","author":"TB Kepler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"e1000305","DOI":"10.1371\/journal.pcbi.1000305","article-title":"Timing the emergence of resistance to anti-HIV drugs with large genetic barriers","volume":"5","author":"P Arora","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/11318110-000000000-00000","article-title":"Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action","volume":"49","author":"C Bazzoli","year":"2010","journal-title":"Clinical pharmacokinetics"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1126\/science.334.6063.1614","article-title":"HIV\/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts","volume":"334","author":"J Cohen","year":"2011","journal-title":"Science (New York, N Y )"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/JVI.02356-09","article-title":"Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS","volume":"84","author":"TW North","year":"2010","journal-title":"Journal of virology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0061102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:56:54Z","timestamp":1715230614000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0061102"}},"subtitle":[],"editor":[{"given":"Mark","family":"Wainberg","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0061102","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]}}}